DUBLIN, Ireland and CHICAGO — November 7, 2025 — Leads & Copy — Iterum Therapeutics plc (Nasdaq: ITRM) will release its third quarter 2025 financial results before the U.S. financial markets open on Friday, November 14, 2025.
Management plans to host a conference call at 8:30 a.m. ET on November 14 to discuss the company’s financial results and business updates.
To access the call, dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 459214. You can pre-register at https://events.q4inc.com/attendee/334189282.
The audio webcast will be available under “Financials & Filings” in the Investors section of Iterum Therapeutics’ website following the call.
Iterum Therapeutics plc focuses on delivering anti-infectives to combat the global crisis of multi-drug resistant pathogens, improving the lives of people affected by serious and life-threatening diseases. The company is advancing the development of its first compound, sulopenem, a novel penem anti-infective with oral and IV formulations. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics.
Iterum has received FDA approval of its NDA for ORLYNVAH™ (oral sulopenem) to treat uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options. The company has also received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
Source: Iterum Therapeutics plc
